PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: PTK787|DRUG: Trastuzumab
Sponsor: Hoosier Cancer Research Network
Collaborators: Novartis Pharmaceuticals|Walther Cancer Institute